- The jab releases 8% aspirin in week one, 13% in week two and 20% by week four
- Aspirin is combined with the sweetener xylitol, which together form a bond
- This bond is slowly broken down, resulting in the drug’s gradual release
- Previous research suggests this would ease the drug’s side effects, like nausea
- Xylitol was chosen as it is harmless and does not interfere with aspirin’s action
Scientists have developed an injection that could see the end of popping painkillers.
The jab, which contains aspirin, releases eight per cent of the drug in the first week, 13 per cent in the second and 20 per cent by week four, new research reveals.
It works by combining aspirin with the sweetener xylitol, which form a bond that is slowly broken down over time, resulting in the drug being gradually released into the bloodstream, a study found.
Previous research demonstrates the painkiller’s gradual release eases its side effects, such as nausea, abdominal pain and drowsiness.
Study author Kaushik Chatterjee, from the Indian Institute of Science in Bangalore, said: ‘Unlike pills that release all the drug at the same time, this would allow the molecule to circulate longer and have a more prolonged effect.’
Scientists have developed an injection that could see the end of popping painkillers (stock)
Reduces side effects and improves patient convenience
As well as easing aspirin’s side effects, the injection could aid patient convenience by removing the need to remember to take medication.
Xylitol, which occurs naturally in fruit and vegetables, was chosen as the molecule to combine with aspirin as it is harmless and does not interfere with the drug’s action.
When the injection was tested with blood cells in the laboratory, the rate aspirin was released reduced inflammation, which plays a role in pain.
Mr Chatterjee said: ‘Unlike pills that release all the drug at the same time, this would allow the molecule to circulate longer and have a more prolonged effect.’
Aspirin is commonly used as a painkiller, as well as blood thinner to prevent conditions such as stroke.
It is unclear when the injection could be available.
The findings were published in the International Journal of Pharmaceutics.